BIOLUX RESEARCH ANNOUNCES FINANCING AND
INVESTIGATIONAL TESTING AUTHORIZATION FOR
THE DEVELOPMENT OF A LIGHT ACCELERATED
ORTHODONTICS PRODUCT

VANCOUVER, B.C., CANADA – Nov. 5, 2009 – Biolux Research Ltd. is pleased to announce that it has issued $860,000 in new shares as part of a new equity offering of common shares.

The offering included a debt conversion vehicle to convert shareholder loans, in which the principal shareholders of the company converted the majority of promissory notes into new shares. The majority of the offering was purchased by Elac Venture Corporation, a private equity investing firm based in Hong Kong. The remainder of the offering was purchased by existing shareholders and individual investors.

The proceeds of the new offering are primarily designated as working capital to finance the initial stages of development of a new product for light accelerated orthodontics. Biolux has also received financial support for this project from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), as reported previously. A portion of the proceeds have been used to eliminate all company debt, resulting in a clean balance sheet for the company.

The company also announces Health Canada approval of an Investigational Testing Authorization application for human feasibility testing of light accelerated orthodontics prototypes. Biolux intends to begin testing this month in Canada.

“We are very pleased by the reception to the share offering, as it supports our concepts and growth prospects for our orthodontics business,” states Kevin Strange, President and CEO of Biolux. “The new capital, plus the IRAP funding and the continuing strength of our existing OsseoPulse™ Bone Regeneration System business, puts us in a strong position to continue developing our light accelerated orthodontic product, and initiate human feasibility testing. Orthodontics represents a very large and important market for us, and we strongly believe that our technology will lead to a revolutionary approach to orthodontics.”

About Biolux Research

Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patent-pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

For More Information:
Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com